Using Interleukin-2 to Treat Advanced Melanoma
Author Information
Author(s): N. Thatcher, H. Dazzi, R.J. Johnson, S. Russell, A.K. Ghosh, M. Moore, G. Chadwick, R.D.P. Craig
Primary Institution: Cancer Research Campaign Department of Medical Oncology, Christie Hospital & Holt Radium Institute, Manchester, UK
Hypothesis
Can intrasplenic and intravenous administration of recombinant interleukin-2 (rIL-2) improve outcomes in patients with advanced malignant melanoma?
Conclusion
The study found that rIL-2 can be effective in treating advanced melanoma, with some patients showing partial responses and improved performance status.
Supporting Evidence
- Four patients had partial tumor responses.
- Six patients remained alive at 9-16 months after treatment.
- Patients' performance status improved despite advanced disease.
Takeaway
Doctors used a special treatment called interleukin-2 to help people with a serious skin cancer called melanoma, and some got better.
Methodology
Patients received rIL-2 intrasplenically and intravenously over several courses, with doses escalated based on tolerance.
Limitations
The study had a small sample size and did not achieve complete responses in patients with multiple metastatic sites.
Participant Demographics
The study included 31 patients, 18 males and 13 females, with a median age of 49 years.
Want to read the original?
Access the complete publication on the publisher's website